{'fraction_non_alphanumeric': 0.0419047619047619, 'fraction_numerical': 0.02666666666666667, 'mean_word_length': 6.013333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor

Results are reported of Trasylol treatment of fifty‐two patients with various forms of urticaria. 100,000 anti‐kallikrein units were given intravenously every other day, with 15–20 injections per course. An excellent therapeutic effect was obtained in 44% (twenty‐three patients), and another 37% (nineteen patients) were greatly improved. Additional evidence of the objective therapeutic benefit was obtained in a double‐blind study (twenty patients).